WebJun 14, 2024 · The idea is that conventional drug development tools such as structure based drug design (championed by Murcko at Vertex), ... With such a strategy, the … WebRelay Therapeutics® is a clinical-stage precision medicine company that sits at the intersection of computational and experimental technologies. We are focused on making …
Who We Are - Relay Therapeutics
WebMar 14, 2024 · The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and … WebDec 8, 2024 · RLY-1971. SHP2 Discovery Programs (5+) While our initial focus has been on enhancing small molecule therapeutic discovery in precision oncology, protein … can a change in diet cause migraines
Strategies to overcome drug resistance using SHP2 …
WebFuture development for RLY-1971 will be governed by a joint development team between us and Genentech. We expect a combination trial of RLY-1971 and Genentech’s KRAS G12C inhibitor, GDC-6036, to be initiated in 2024. Given the range of cancers that are related to SHP2 dependence, we believe RLY-1971 could serve as a backbone for compelling ... WebJan 29, 2024 · This study is a multi-center, open-label, dose escalation and expansion study of RLY-1971 in subjects with advanced or metastatic solid tumors. RLY-1971 in Subjects … WebDocument code : BPI/EPP/2006/PI/2 REV. (Only in Eng, Fre) Collation : 123 p., illus. Language : English Also available in : Français Also available in : Español Year of publication : 2006 can a change in diet cause constipation